HRGN (Harvard Apparatus Regenerative Technology) EBIT: $-6.80 Mil (TTM As of Mar. 2026)

What is Harvard Apparatus Regenerative Technology EBIT?

Harvard Apparatus Regenerative Technology HRGN 34 EBIT is $-6.80 Mil as of Mar. 2026. GuruFocus rates HRGN with a GF Score™ of 34/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review.

Harvard Apparatus Regenerative Technology's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-1.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Harvard Apparatus Regenerative Technology's annualized ROC % for the quarter that ended in Mar. 2026 was -494.92%. Harvard Apparatus Regenerative Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3,420.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Harvard Apparatus Regenerative Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -28.12%.

Harvard Apparatus Regenerative Technology (OTCPK:HRGN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Harvard Apparatus Regenerative Technology's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-6.424 * ( 1 - 0% )	/	( (1.213	+	1.383)	/ 2 )
=	-6.424	/	1.298
=	-494.92 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.677	-	1.169	-	( 1.352	-	max(0, 1.534	-	1.829	+	1.352	))
=	1.213

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.798	-	1.193	-	( 0.419	-	max(0, 1.651	-	0.873	+	0.419	))
=	1.383

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Harvard Apparatus Regenerative Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.396	/	( ( (0.201 + max(-0.944, 0))	+	(0.173 + max(-1.079, 0)) )	/	2 )
=	-6.396	/	( ( 0.201	+	0.173 )	/	2 )
=	-6.396	/	0.187
=	-3,420.32 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.016	+	0.016	+	0.445)	-	(1.169	+	0.252	+	0)
=	-0.944

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.016	+	0.015	+	0.423)	-	(1.193	+	0.34	+	0)
=	-1.079

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Harvard Apparatus Regenerative Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-6.803	/	24.191
	=	-28.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology EBIT Related Terms

Harvard Apparatus Regenerative Technology EBIT Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's EBIT can be seen below:

Harvard Apparatus Regenerative Technology EBIT Chart

Harvard Apparatus Regenerative Technology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-8.47

-6.06

-8.93

-7.69

-6.86

Harvard Apparatus Regenerative Technology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-1.66	-1.82	-1.70	-1.69	-1.60

HRGN vs DTEAF, WYGC, BFNH: EBIT Comparison

For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harvard Apparatus Regenerative Technology EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's EV-to-EBIT falls into.

Save Embed

34GF Score

Harvard Apparatus Regenerative Technology Inc HRGN

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Harvard Apparatus Regenerative Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.80 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-6.80 Mil mean?

Harvard Apparatus Regenerative Technology (HRGN) has a EBIT of $-6.80 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Harvard Apparatus Regenerative Technology.

Is Harvard Apparatus Regenerative Technology's EBIT too high?

Harvard Apparatus Regenerative Technology's current EBIT is $-6.80 Mil. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Harvard Apparatus Regenerative Technology's EBIT compare to DTEAF and WYGC?

Harvard Apparatus Regenerative Technology's EBIT of $-6.80 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Consumer Packaged Goods company?

A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Harvard Apparatus Regenerative Technology. Harvard Apparatus Regenerative Technology's current EBIT is $-6.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Harvard Apparatus Regenerative Technology stock overvalued right now?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current EBIT is $-6.80 Mil. Harvard Apparatus Regenerative Technology's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current EBIT is $-6.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

EBIT: $-6.80 Mil
GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
GF Score™: 34/100 with 2 warning signs

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Apparatus Regenerative Technology Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies DTEAF WYGC BFNH LIMX STCB FAMI COOT JVA CTGL NAII XSWX:NESN XPAR:BN BOG:NUTRESA TSE:2802 SHSE:603288 NSE:NESTLEIND KHC SHSE:600887 SZSE:300999 GIS

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746

Website https://www.biostage.com

Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.

34GF Score

Get the complete analysis for HRGN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39

Price

$5.34

GF Value

View HRGN Analysis

See EBIT data for all stocks →